YouTube Facebook LinkedIn Google+ Twitter Xingrss  

Expensive Gene Therapy Approved in Europe


November 5, 2012 | Europe has approved an expensive gene therapy. Glybera treats the genetic disorder lipoprotein lipase deficiency (LPLD) and will cost around 1.2 million euros ($1.6 million) per patient. Reuters 
View Next Related Story
Click here to login and leave a comment.  

0 Comments

Add Comment

Text Only 2000 character limit

Page 1 of 1


For reprints and/or copyright permission, please contact  Terry Manning, 781.972.1349 , tmanning@healthtech.com.